Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesChristoph Wanner, Bernard Zinman|New England Journal of Medicine|2016Cited by 3.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney DiseaseDick de Zeeuw, Glenn M. Chertow, Tadao Akizawa et al.|New England Journal of Medicine|2013Cited by 990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Jonathan Emberson et al.|The Lancet|2022Cited by 969
CKD Prevalence Varies across the European General PopulationKatharina Brück, Kitty J. Jager, Vianda S Stel et al.|Journal of the American Society of Nephrology|2015Cited by 588
Everolimus in Patients with Autosomal Dominant Polycystic Kidney DiseaseGerd Walz, Kai‐Uwe Eckardt, Klemens Budde et al.|New England Journal of Medicine|2010Cited by 574